CCA
NRXP icon

Column Capital Advisors’s NRX Pharmaceuticals NRXP Stock Holding History

Column Capital Advisors’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10
Closed -$66 – 831
2023
Q1 		$66 Hold
10
– – ﹤0.01% 821
2022
Q4 		$111 Buy
+10
New +$101 ﹤0.01% 821

Other funds holding NRXP

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Column Capital Advisors's NRXP Position: Q2 2023 in Review

Column Capital Advisors sold out of NRX Pharmaceuticals (NRXP) in Q2 2023, closing a stake of 10 shares — an estimated $66 sold.

Column Capital Advisors first reported a position in NRXP in Q4 2022 and held it in 2 quarters. The position peaked at $111 in Q4 2022. 32 funds tracked by Wall St. Rank hold NRXP as of Q2 2023.

  • Column Capital Advisors reported no remaining NRX Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Column Capital Advisors sold 10 NRX Pharmaceuticals shares in Q2 2023, an estimated $66.
  • Column Capital Advisors first reported a position in NRX Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Column Capital Advisors's NRX Pharmaceuticals position peaked at $111 in Q4 2022.
  • 32 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2023.

Based on Column Capital Advisors's 13F filing for Q2 2023, filed 8 Aug 2023.